Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$9.07 +1.2%	$7.90	$6.85 ▼ $24.76	$528.77M	-0.04	572,966 shs	307,735 shs
HRMY Harmony Biosciences	$35.16 -0.4%	$31.67	$26.47 ▼ $41.61	$2.02B	0.87	613,175 shs	646,693 shs
KNSA Kiniksa Pharmaceuticals	$28.88 -0.8%	$23.96	$17.38 ▼ $29.71	$2.11B	0.06	497,679 shs	815,740 shs
VCEL Vericel	$43.17 +3.8%	$41.28	$37.39 ▼ $63.00	$2.17B	1.31	417,391 shs	549,264 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	+2.40%	+14.58%	+1.93%	+6.29%	-60.25%
HRMY Harmony Biosciences	-0.70%	+4.50%	+16.46%	+4.65%	+17.78%
KNSA Kiniksa Pharmaceuticals	+4.26%	+9.89%	+5.28%	+36.09%	+47.69%
VCEL Vericel	+2.74%	-1.19%	+6.73%	-19.33%	-10.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	2.2511 of 5 stars	3.5	2.0	2.2	1.7	0.6
HRMY Harmony Biosciences	4.9492 of 5 stars	4.6	4.0	3.6	3.3	4.4
KNSA Kiniksa Pharmaceuticals	2.9993 of 5 stars	3.5	2.0	3.2	3.3	0.6
VCEL Vericel	3.2504 of 5 stars	3.5	3.0	3.2	0.8	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$32.00	252.81% Upside
HRMY Harmony Biosciences	3.11	Buy	$53.00	50.74% Upside
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	34.35% Upside
VCEL Vericel	3.00	Buy	$61.14	41.63% Upside

Current Analyst Ratings Breakdown

Latest CGEM, HRMY, KNSA, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/22/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/29/2025	KNSA Kiniksa Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
4/16/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
4/16/2025	KNSA Kiniksa Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00
4/11/2025	VCEL Vericel	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $51.00

(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.61 per share	N/A
HRMY Harmony Biosciences	$744.85M	2.71	$2.63 per share	13.38	$7.97 per share	4.41
KNSA Kiniksa Pharmaceuticals	$481.17M	4.38	N/A	N/A	$6.23 per share	4.64
VCEL Vericel	$238.54M	9.11	$0.01 per share	3,081.95	$4.73 per share	9.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$153.16M	-$2.91	N/A	N/A	N/A	N/A	-26.54%	-25.32%	8/14/2025 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.62	16.66	11.31	0.47	17.98%	23.16%	14.24%	8/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	115.52	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)
VCEL Vericel	-$3.18M	$0.03	719.62	98.11	N/A	1.56%	1.48%	0.96%	7/30/2025 (Estimated)

Latest CGEM, HRMY, KNSA, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/8/2025	Q1 2025	VCEL Vericel	-$0.09	-$0.23	-$0.14	-$0.23	$53.86 million	$52.60 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	24.46	24.46
HRMY Harmony Biosciences	0.28	3.24	3.20
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95
VCEL Vericel	N/A	4.61	4.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
HRMY Harmony Biosciences	86.23%
KNSA Kiniksa Pharmaceuticals	53.95%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
HRMY Harmony Biosciences	23.60%
KNSA Kiniksa Pharmaceuticals	54.57%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.02 million	54.69 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	39.47 million	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.97 million	32.80 million	Optionable
VCEL Vericel	300	50.34 million	46.79 million	Optionable

CGEM, HRMY, KNSA, and VCEL Headlines

Recent News About These Companies

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 16,466 Shares of Vericel Co. (NASDAQ:VCEL)

June 3 at 3:57 AM | marketbeat.com

Wellington Management Group LLP Buys 701,064 Shares of Vericel Co. (NASDAQ:VCEL)

May 30, 2025 | marketbeat.com

Voloridge Investment Management LLC Acquires Shares of 27,345 Vericel Co. (NASDAQ:VCEL)

May 30, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Earns Overweight Rating from Stephens

May 25, 2025 | americanbankingnews.com

Vericel's (VCEL) Overweight Rating Reiterated at Stephens

May 24, 2025 | marketbeat.com

Vericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AG

May 24, 2025 | marketbeat.com

5VCEL : What Analysts Are Saying About Vericel Stock

May 23, 2025 | benzinga.com

Vericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial Markets

May 23, 2025 | marketbeat.com

Rafferty Asset Management LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)

May 22, 2025 | marketbeat.com

Lazard Asset Management LLC Purchases 5,923 Shares of Vericel Co. (NASDAQ:VCEL)

May 22, 2025 | marketbeat.com

Soleus Capital Management L.P. Purchases Shares of 80,696 Vericel Co. (NASDAQ:VCEL)

May 21, 2025 | marketbeat.com

Vericel Co. (NASDAQ:VCEL) Holdings Raised by D. E. Shaw & Co. Inc.

May 20, 2025 | marketbeat.com

Ameriprise Financial Inc. Sells 124,122 Shares of Vericel Co. (NASDAQ:VCEL)

May 19, 2025 | marketbeat.com

Vericel at BofA Securities Conference: Growth and Innovation in Healthcare

May 17, 2025 | investing.com

Vericel Co. (NASDAQ:VCEL) Given Consensus Rating of "Buy" by Brokerages

May 15, 2025 | marketbeat.com

StockNews.com Downgrades Vericel (NASDAQ:VCEL) to Sell

May 15, 2025 | marketbeat.com

Northern Trust Corp Buys 44,397 Shares of Vericel Co. (NASDAQ:VCEL)

May 13, 2025 | marketbeat.com

Leerink Partnrs Has Positive Outlook of Vericel Q4 Earnings

May 13, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Issues Earnings Results

May 12, 2025 | marketbeat.com

First Trust Advisors LP Lowers Stock Holdings in Vericel Co. (NASDAQ:VCEL)

May 12, 2025 | marketbeat.com

Frontier Capital Management Co. LLC Has $15.82 Million Stock Holdings in Vericel Co. (NASDAQ:VCEL)

May 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, HRMY, KNSA, and VCEL Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$9.07 +0.11 (+1.23%)

As of 04:00 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Harmony Biosciences NASDAQ:HRMY

$35.16 -0.15 (-0.42%)

As of 04:00 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Kiniksa Pharmaceuticals NASDAQ:KNSA

$28.88 -0.23 (-0.79%)

As of 04:00 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Vericel NASDAQ:VCEL

$43.17 +1.60 (+3.85%)

As of 04:00 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time